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Mechanisms controlling the p53 regulatory 
network remain the focus of numerous inves-
tigations in hopes of identifying more robust 
cancer therapies. Both Mdm2 and MdmX are 
found overexpressed in tumors with wild-type 
p53 and represent a key molecular device 
modulating p53 function. Thus, examining 
the interplay between these three proteins 
becomes highly relevant in the search for new 
pharmacological interventions in oncology.
Mdm2 is a RinG-type e3 ubiquitin ligase 
capable of forming homo-oligomers and 
hetero-oligomerization with MdmX via the 
extreme C termini of their RinG domains. since 
its discovery 15 years ago, MdmX has been 
assigned many roles in the regulation of p53, 
either on its own or in concert with Mdm2. 
while clearly an essential negative regulator or 
p53 in development, its lack of intrinsic ubiqui-
tin ligase activity has made the mechanism of 
p53 regulation more elusive than in the case 
of Mdm2. The capacity of MdmX to stimulate 
Mdm2-mediated p53 ubiquitination was first 
reported in 2003.1 subsequent biochemical 
comparisons of the activity of Mdm2–MdmX 
complexes showed that not only does the 
presence of MdmX in the complex alter the 
substrate specificity of the holo-enzyme, it 
also allows for poly-ubiquitin chain forma-
tion on p53 (modification required for nuclear 
exclusion and degradation of p53).2-4
in vitro observations describing the 
importance of the MdmX RinG domain in 
regulation of p53 turnover have now gained 
in vivo experimental support from the two 
knock-in animal models.5,6 Consistent with the 
notion that MdmX is an essential component 
of p53 polyubiquitination/proteasomal deg-
radation pathway, mice expressing either a 
point mutant in the MdmX RinG domain or a 
RinG domain deletion mutant succumbed to 
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a p53-dependent embryonic lethality. These 
data implicate the RinG domain of MdmX as 
the sole region of importance in the ability of 
MdmX to regulate p53 and, by extension, the 
Mdm2-MdmX complex (and not the Mdm2 
homodimer), as the principle negative regula-
tor of p53 activity during development.
The growing body of evidence describ-
ing the presence of MdmX in the complex 
as crucial for target selectivity as well as the 
processivity of the holoezyme somewhat flies 
in the face of the existing structural data. Two 
published structures of the Mdm2 homodimer 
and Mdm2/MdmX heterodimer indicate virtu-
ally no difference in the complexes.7,8 in the 
absence of structural differences, how then 
are such significant differences in function 
accomplished? 
A hypothesis unifying structural and func-
tional data is brought forth by a very intriguing 
study from the Uldrijan group, which sys-
tematically looks at the differences between 
complex formation and activity of Mdm2 and 
MdmX.9 Phylogenetic analysis showed that the 
last cystein of the RinG domain is followed by 
exactly 13 amino acids in all Mdm orthologs 
of vertebrate origin. Based on this, the authors 
hypothesized that not only the sequence of 
the C-terminal tails, but also their exact length 
are of central importance to the function of 
the complexes. subsequent investigation 
of the ability of Mdm2 and MdmX proteins, 
which have been extended at the C terminus 
by 5, 14 or 18 amino acids, was designed 
to test the importance of the length of the 
C-terminal extensions. To the researchers sur-
prise, when examined based on their ability 
to hetero-oligomerize and ubiquitinate p53, 
Mdm2 proteins behaved differently depend-
ing on whether the oligomeric partner was 
Mdm2 or MdmX. 
Dolezelova et al. present unexpected 
experimental evidence for the heterocomplex 
being structurally and functionally distinct 
from the Mdm2 homodimer, while providing 
a mechanism for the observed in vivo func-
tional differences between the complexes. 
Although the work casts slight doubt on the 
complete accuracy of the existing structures, 
it nicely aligns with the above-mentioned 
results, showing the singular importance of 
the MdmX RinG domain in the activity of the 
holoenzyme. in light of these results, addi-
tional structural studies that will take in to 
account reported differences between the 
complexes will undoubtedly be informative 
and contribute to our understanding of the 
biochemistry of RinG-type ubiquitin ligases 
and the mechanisms regulating p53 in cells.
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More than 90% of human cancers are of epithe-
lial origin. Cellular senescence of human mam-
mary epithelial cells (HMeCs) is an important 
barrier that protects cells from immortalization; 
the first step in breast cancer development.1 
Although induction of tumor suppressor p16 
is not evident in some types of normal human 
fibroblasts undergoing senescence,2 in cul-
tured HMeCs, senescence occurs by a robust 
p16 induction, and cells that acquire silencing 
of  p16Ink4a locus eventually proliferate and 
undergo senescence again by telomere short-
ening in a p53-dependent manner.1 Therefore, 
p16 induction is a critical barrier to immortalize 
HMeCs in culture. p16 inhibits kinase activity 
of Cdk4/6-cyclinD complexes, which inactivate 
three pRb family proteins: pRb, p107 and p130. 
However, the relative contribution of these 
three pRb family proteins to HMeC senescence 
is not well understood.
in a recent issue of Cell Cycle, Bazarov et al. 
examined the role of each pRb family protein 
in p16-mediated senescence in breast cancer 
cell lines and in HMeCs (Fig. 1).3 They showed 
that knockdown of each of the three pRb 
family proteins individually did not abrogate 
senescence mediated by ectopically expressed 
p16 in the breast cancer cell lines MDA-MB-231 
and MCF7. However, the senescence induced 
by ectopic p16 was abrogated if they intro-
duced e7, which inactivates all three pRb fam-
ily proteins. Their data suggest that two of 
pRb family proteins can compensate for the 
loss of each pRb family protein to induce 
p16-mediated senescence in these cancer 
cells. The remaining question is whether all 
three pRb family members play an additive 
role, and whether the inactivation of at least 
two members of the pRb family is required to 
overcome p16-induced senescence in breast 
cancer cells. On the other hand, they showed 
that abrogation of pRb, but not of p107 and/ or 
p130, attenuates senescence in HMeCs, sug-
gesting a non-redundant critical role of pRb in 
HMeC senescence. These data are consistent 
with a recent report demonstrating that pRb 
has a non-redundant role in repressing DnA 
replication during H-ras-induced senescence 
of human fibroblasts,4 and explain why pRb, 
but not p107 or p130, is frequently mutated in 
cancer. interestingly, although abrogation of 
pRb is critical for HMeCs escaping senescence, 
simultaneous depletion of pRb together with 
either p107, p130 or both accelerates bypass of 
senescence. This suggests that p107 and p130 
help pRb to trigger/maintain HMeC senes-
cence in culture and possibly in vivo. Although 
each pRb family protein preferentially binds to 
different members of the e2F family,5 the con-
tribution of each e2F family protein in escap-
ing p16-mediated senescence remains unclear. 
Therefore, it will be interesting to see whether 
the critical role of pRb, and a supportive role of 
p130 and p107, in p16-mediated HMeC senes-
cence depend on how each pRb family protein 
interacts with an e2F family protein.
Bazarov et al. also showed that even aggres-
sive p53-negative breast cancer cells undergo 
cellular senescence upon ectopic p16 expres-
sion. These results are quite encouraging from 
an epigenetic therapy point of view. silencing 
of p16 often occurs in breast cancer cells via 
promoter methylation. During DnA replica-
tion, cells require new p16 promoter methyla-
tion to keep p16 silenced. The observations of 
Bazarov et al. suggest that we may be able to 
stop the growth of even aggressive p53-nega-
tive breast cancers in patients by inducing p16 
expression in cancer cells using DnA methyla-
tion inhibitors. Back to the question of running 
family business: “it appears that pRb is still the 
boss, but in some cases, it may get a helping 
hand from his cousins- p107 and p130.”
References
1.  stampfer MR, et al. Cancer Lett 2003; 194:199-208; 
PMiD:12757978; http://dx.doi.org/10.1016/s0304-
3835(02)00707-3.
2.  itahana K, et al. Mol Cell Biol 2003; 23:389-401; 
PMiD:12482990; http://dx.doi.org/10.1128/
MCB.23.1.389-401.2003.
3.  Bazarov Av, et al. Cell Cycle 2012; 11:1008-13; 
PMiD:22333593; http://dx.doi.org/10.4161/
cc.11.5.19492.
4.  Chicas A, et al. Cancer Cell 2010; 17:376-87; 
PMiD:20385362; http://dx.doi.org/10.1016/j.
ccr.2010.01.023.
5.  Classon M, et al. nat Rev Cancer 2002; 2:910-7; 
PMiD:12459729; http://dx.doi.org/10.1038/nrc950.
pRb or its cousins: Who controls the family business?
Comment on: Bazarov AV, et al. Cell Cycle 2012; 11:1008–13; PMID:22333593; 
http://dx.doi.org/10.4161/cc.11.5.19492
Koji Itahana1 and Goberdhan P. Dimri2,*; 1Duke-NUS Graduate Medical School; Singapore; 2George Washington University Medical Center; Washington, DC USA; 
*Email: gdimri@gwu.edu; http://dx.doi.org/10.4161/cc.20048
Figure 1. Contribution of pRb family proteins to p16-mediated senescence in breast cancer cells 
and HMeCs. Knockdown of each of the three pRb family proteins in breast cancer cells does not 
abrogate ectopic p16-induced senescence, suggesting that either two of pRb family proteins can 
compensate for the loss of each pRb family proteins or all three of pRb family proteins play an 
additive role in p16-mediated senescence in breast cancer cells. On the other hand, knockdown of 
pRb, but not of p107 or p130, abrogates HMeC senescence, suggesting a non-redundant critical role 
for pRb in senescence of HMeCs. However, the knockdown of either p107 or p130, in conjunction 
with pRb depletion, abrogates HMeC senescence more efficiently than pRb knockdown alone. This 
suggests a supporting role for p107 and p130 in maintaining HMeC senescence.© 2012 Landes Bioscience.
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investment in the post-genomic molecular 
dissection of breast cancer has resulted in an 
emphasis on prognostic and predictive mark-
ers, signatures derived to stratify the disease 
and the drive to generate targeted therapies. 
However, there remain significant challenges 
to individualize therapeutic targeting and 
improve the prognosis for the thousands of 
women who die each year from the heteroge-
neous range of breast cancers. This is particu-
larly true for poor prognosis “triple-negative” 
breast cancers (TnBC), most prevalent in 
young and African American women, lacking 
the established therapeutic targets of estro-
gen receptor, progesterone receptor or HeR2.
Research has largely focused on the epi-
thelial component of breast cancer rather than 
the tumor microenvironment, now recognized 
as a key hallmark of cancer.1 in vitro, animal 
models and observations on clinical material2 
are now moving to consider physiological 
mechanisms by which stromal cells may influ-
ence breast epithelial and carcinoma cells.
witkiewicz et al.3 build on published evi-
dence from the Lisanti group that cancer cells 
secrete hydrogen peroxide, initiating oxidative 
stress and aerobic glycolysis in tumor stroma, 
with L-lactate secretion from cancer-associ-
ated fibroblasts fueling oxidative mitochon-
drial metabolism in epithelial cancer cells: the 
“reverse warburg effect.”
They demonstrate stromal monocarboxyl-
ate transporter 4 (MCT4), detected by immu-
nohistochemistry, as a functional marker of 
stromal hypoxia, oxidative stress, aerobic gly-
colysis and L-lactate efflux. High stromal MCT4 
expression (but, critically, not epithelial MCT4) 
was associated with poor prognosis in TnBC 
patients. Combined high stromal MCT4 and 
loss of stromal caveolin-1 identify particularly 
poor prognostic TnBC.
Thus, development of cancer may not lie 
solely in genetic or epigenetic epithelial 
changes, but with acquired functional changes 
in the stromal infrastructure of the breast. This 
supports the concept of epithelial malignant 
changes consequent with ecological and evo-
lutionary opportunity.4
 The “parasitic” character of tumor cells 
feeding off stromal cells highlights the need 
to seriously consider both ecological and bio-
physical concepts.5 we need to think beyond 
“intraspecific” competition among clonal sub-
populations in the tumor and to consider 
tumor and stromal cells as distinct popula-
tions in a cancer ecosystem, with a range of 
“interspecific” competitive, exploitative and 
opportunistic interactions. Furthermore, the 
reverse warburg effect relies on the inefficient 
diffusion of nutrients from stromal cells to 
tumor cells in a complex three-dimensional 
space. The extracellular space is brought to 
the foreground, and physical properties of 
molecular transport in this space may have 
as much impact on tumor growth as intricate 
cellular processes.
 The importance of the spatial arena is 
also apparent when contrasting the reverse 
warburg effect with angiogenesis. in the for-
mer, tumor cells are exploiting their local envi-
ronment, which will presumably be of limited 
yield, whereas angiogenesis taps the nutrients 
of the entire organism—  an effectively infinite 
reservoir for a growing tumor. in the reverse 
warburg effect, a balance of ecological and 
biophysical factors underpins the sustainabil-
ity of this mode of cancer nutrition.
 A two-compartment model coupling oxi-
dative epithelial cells with glycolytic fibroblasts 
reflects increased expression of hypoxia-asso-
ciated genes as a component part of prog-
nostic stromal signatures.6 Further evidence of 
stromal/epithelial interaction comes from evi-
dence that the effects of radiation on normal 
breast epithelium in vivo is at least partially 
dependent on the stromal context.7
Manipulation of the tumor microenviron-
ment to promote an anticancer phenotype 
challenges the cancer treatment paradigm. 
The long-established antidiabetes biguanide 
drugs offer a low-toxicity opportunity to dis-
rupt the reverse warburg effect. Metformin 
may target the cancer mitochondria3 and 
phenformin induce stromal sclerosis, at least in 
a breast cancer xenograft model,8 in addition 
to in vivo AMPK pathway and insulin-mediated 
systemic effects of metformin in women with 
breast cancer.9
 The reverse warburg effect challenges our 
therapeutic focus on breast cancer epithelium. 
stromal MCT4 expression with caveolin-1 loss 
identifies poor prognostic TnBC patients and 
emphasizes the roles of the tumor microenvi-
ronment and ecological interactions between 
distinct populations of cells. The challenges 
now revolve around therapeutic manipula-
tion of the stroma/epithelial interaction and 
the extracellular space, and testing these con-
cepts in pre-invasive and metastatic settings 
where stromal changes may provide tissue 
niches of evolutionary opportunity for malig-
nant cells.
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in an exciting and surprising paper in a recent 
issue of Cell Cycle, Leidecker et al. show that 
the balance between protein modification by 
ubiquitin or the ubiquitin like protein neDD8 
is dramatically altered by cellular stress. in 
a variety of conditions that reduce the con-
centration of free ubiquitin, a very dramatic 
increase in protein modification by ned-
dylation is revealed. importantly, this process 
is shown to arise as neDD8 is activated under 
these conditions by the ubiquitin-activating 
enzyme Ube1 and not by the typical neDD8 
specific ei enzyme, nAe. This results in many 
proteins in stressed cells being modified by 
mixed ubiquitin neDD8 chains, which is highly 
relevant in the development of novel can-
cer therapeutics, as the nAe specific inhibitor 
MLn49242does not block this new pathway 
despite its promising anticancer activity.
initial comparative studies on the ubiqui-
tin and ubiquitin-like (Ubl) protein pathways 
have established that each pathway has sepa-
rate and specific enzymes both for activating 
the Ubl and for removing it.3 in the case of 
neDD8, the e1 is nAe; the e2s are Ubc12 and 
Ube2F, and the e3s include the Rbx1 and Rbx2 
RinG finger proteins as well as members of 
the DCn family of proteins. The first studies 
of the neDD8 system suggested that there 
were very few substrates for this modifica-
tion, with most emphasis placed on the cullin 
proteins. The cullins are components of the 
cullin-RinG ligases (CRLs) that are responsible 
for the ubiquitylation of many critical sub-
strates, for example, oncoproteins such as 
cyclin e and c-myc. The cullins are modified 
by neddylation, which increases the e3 activ-
ity of the CRLs, probably through structural 
alterations that free the Ring domain of the e3 
and/or by blocking the binding of inhibitory 
proteins such as CAnD 1.4,5 Recently, many 
new substrates and e3 ligases for neDD8 have 
been uncovered, with initial studies identify-
ing p53 and Mdm2 as substrates for ned-
dylation, and Mdm2 as a e3 ligase for both 
neDD8 and ubiquitin.6 Proteomic approaches 
have now identified many more substrates, 
notable among them being the ribosomal 
proteins involved in signaling to p53.7,8 in the 
current study, the authors found that a high 
level of neDD8-conjugated proteins were rap-
idly induced by proteasome inhibition with 
MG132, but that this reaction was not inhib-
ited by MLn4924, even while the same com-
pound was blocking cullin neddylation. This 
meant that another e1 had to be in play for 
the neddylation of these new substrates, and 
knockdown of Ube1 (which was known to be 
able to activate neDD8 in vitro)9 showed that 
it was, indeed, responsible. exploring further 
stress signals showed that this increased ned-
dylation response was induced by heat shock 
and by elevated levels of reactive oxygen 
species (ROs). since all of these stress path-
ways reduce free ubiquitin levels, the authors 
asked if nAe-independent neddylation could 
be triggered simply by reducing free ubiquitin 
levels. The clearly positive results of this study 
suggested that competition with ubiquitin 
for Ube1 may normally limit Ube1 activation 
of neDD8 and the neddylation of non-cullin 
substrates (Fig. 1). 
in stress conditions then, when free ubiqui-
tin levels fall, Ube1 acts as a sensor of this state 
and neddylation increases. why would this 
be useful? The speculation is that the modi-
fication of substrate proteins by neDD8 may 
help the cell to cope with stress signals, for 
example, by promoting cell survival through 
inhibition of the degradation of very labile 
pro-survival proteins, such as Mcl-1. After the 
stress signal abates, the many effective de-
ubiquitinating and de-neddylating enzymes 
can come into play to restore homeostasis. 
improved mass spectrometry methods devel-
oped in this paper using Lys-C to digest ned-
dylated proteins allow one to distinguish 
neDD8 modification from ubiquitination. This 
helps to further refine our knowledge of this 
fascinating system, but, meanwhile, protein 
neddylation may provide a new biomarker for 
cellular stress. Many critical issues remain to 
be resolved: are there proteins with ubiqui-
tin/neDD8 binding domains that specifically 
recognize the ubiquitin neDD8 hybrid chains 
that result from these stress signals? which 
e2s and e3s are responsible for stress-induced 
neddylation? should Ube1 inhibitors be devel-
oped to complement the nAe inhibitor in 
cancer treatments, or would they prove too 
toxic? The next few years promise to reveal 
critical insights into the crosstalk between the 
different Ubl pathways.
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Figure 1. nedd8 pathway and stress. (A) in unstressed cells, two parallel and non-overlapping pathways are in play. nedd8 activation is through the 
action of nAe, while ubiquitin is activated by Ube1. substrate selectivity of the e2 and e3 results in many proteins being ubiquitinated, but few are 
nedd8-modified, notably, the cullins. (B) Low free ubiquitin levels in stress conditions results in nedd8 being activated by the ubiquitin Ube1 as well as 
nAe1. This, in turn, results in a large increase in the variety of protein substrates that are neDD8-modified, in addition to the cullins.